Category Archives: Epigenetics

This article was originally published here

Curr Environ Health Rep. 2022 Jun 1. doi: 10.1007/s40572-022-00353-9. Online ahead of print.

ABSTRACT

PURPOSE OF REVIEW: Several environmental contaminants have been implicated as contributors to COVID-19 susceptibility and severity. Immunomodulation and epigenetic regulation have been hypothesized as mediators of this relationship, but the precise underlying molecular mechanisms are not well-characterized. This review examines the evidence for epigenetic modification at the intersection of COVID-19 and environmental chemical exposures.

RECENT FINDINGS: Numerous environmental contaminants including air pollutants, toxic metal(loid)s, per- and polyfluorinated substances, and endocrine disrupting chemicals are hypothesized to increase susceptibility to the SARS-CoV-2 virus and the risk of severe COVID-19, but few studies currently exist. Drawing on evidence that many environmental chemicals alter the epigenetic regulation of key immunity genes and pathways, we discuss how exposures likely perturb host antiviral responses. Specific mechanisms vary by contaminant but include general immunomodulation as well as regulation of viral entry and recognition, inflammation, and immunologic memory pathways, among others. Associations between environmental contaminants and COVID-19 are likely mediated, in part, by epigenetic regulation of key immune pathways involved in the host response to SARS-CoV-2.

PMID:35648356 | DOI:10.1007/s40572-022-00353-9

Link:
Epigenetics at the Intersection of COVID-19 Risk and Environmental Chemical Exposures - DocWire News

The detailed analysis of the global Epigenetics Instrument market delivers key insights on the changing industry dynamics, value chain analysis, leading investment pockets, competitive scenarios, regional landscape, and crucial segments. It also offers an extensive inspection related to the driving and restraining ingredients for the global Epigenetics Instrument market. Additionally, explains the superior data about the working strategies and growth prospects of the global Epigenetics Instrument market. This will help industry players, policymakers, stakeholders, investors, and new aspirants to grab innovative opportunities, uncover important strategies, and also accomplish a competitive edge in the global Epigenetics Instrument Industry.

Get a FREE PDF Sample of the Global Epigenetics Instrument Market Report: https://marketresearchexpertz.com/report/global-epigenetics-instrument-market-496301#request-sample

The report delivers a comprehensive evaluation of the Epigenetics Instrument market globally for the forecasted period through 2022-2029. The global Epigenetics Instrument market report comprises different marketing components and the future trends that are performing a substantial role in the Epigenetics Instrument industry. The factors such as the drivers, opportunities, challenges, and restraints will impact the Epigenetics Instrument market growth across the world. Moreover, the Epigenetics Instrument market report gives a deep outlook on the implementation of the Epigenetics Instrument market in terms of revenue throughout the projected period.

The study pays attention to the loftiest revenue-generating and highest growing segments of the Epigenetics Instrument market. All these insights help explore strategies and accomplish sustainable growth in the Epigenetics Instrument market. This makes the research document accurately organized and systematic alongside encouraging a simpler understanding of each facet covered in this report.

The research also offers deep segmentation of the global Epigenetics Instrument market 2022 based on the specific region, well-established players, applications, and product types. The global Epigenetics Instrument market report also offers a comprehensive analysis of each segment of the Epigenetics Instrument market. The insights on the Epigenetics Instrument market report are valuable in evaluating distinct components such as analyzing expansion strategies, finding growth potential, and focusing on opportunities that are available in new regions/countries.

If You Have a Any Query for Buying A Report or Customization of Report Click Here: https://marketresearchexpertz.com/report/global-epigenetics-instrument-market-496301#inquiry-for-buying

Vital Players covered in the Epigenetics Instrument Market report:

Illumina (US)Thermo Fisher (US)Diagenode (Belgium)QIAGEN (Netherlands)Merck Millipore (US)Abcam (UK)Active Motif (US)New England Biolabs (US)Agilent (US)Zymo Research (US)PerkinElmer (US)Bio-Rad (US)

Product Types of the Epigenetics Instrument market are as follows:

Next-generation SequencersqPCR InstrumentsMass SpectrometersSonicatorsOther

Key Applications included in the Epigenetics Instrument market:

OncologyMetabolic DiseasesDevelopmental BiologyImmunologyCardiovascular DiseasesOther

Regional analysis of the Epigenetics Instrument market:

North America Market(United States, Canada, North American country and Mexico),Europe Market (Germany, Epigenetics Instrument France, UK, Russia and Italy),Asia-Pacific Market (China, Epigenetics Instrument Japan and Korea, Asian nation, India and Southeast Asia),South America Market (Brazil, Argentina, Republic of Colombia etc.),Middle East & Africa Market (Saudi Arabian Peninsula, UAE, Egypt, Nigeria and South Africa)

The new study on the global Epigenetics Instrument market report provides a detailed impact of the COVID-19 pandemic on the Epigenetics Instrument market in order to support the worldwide industry players, suppliers, investors, and various other competitors to recapture their strategies, attain new patterns, and meanwhile, take some necessary steps to survive through the pandemic. Furthermore, the report on the Epigenetics Instrument market delivers high-quality information and statistics related to the world Epigenetics Instrument market. Our professional research report will help you to establish accurate data tables and assigns the utmost accuracy in the Epigenetics Instrument industry forecasting.

Read Complete Analysis Report for Better Understanding (Description, TOC, List of Tables & Figures and Many More): https://marketresearchexpertz.com/report/global-epigenetics-instrument-market-496301

Prominent Highlights of the Global Epigenetics Instrument Market Report:

It demonstrates the overall competitive landscape of the global Epigenetics Instrument market. Revenue produced by each segment of the Epigenetics Instrument market by 2029. It covers different industrial factors that are anticipated to drive and generate newer opportunities in the Epigenetics Instrument market. The report on the Epigenetics Instrument market also illustrates several strategies to climb sustainable growth of the Epigenetics Instrument industry. It displays the tactics used by the leading players and product offerings. Exhibits geographical regions that would develop excellent business opportunities during the predicted timeframe from 2022 to 2029. The global Epigenetics Instrument market report covers, revenue shares, sale assessment, gross margin, historical growth analysis, and upcoming perspectives in the Epigenetics Instrument market.

Contact Us:

Market Research ExpertzEmail : sales@marketresearchexpertz.comWebsite : https://marketresearchexpertz.com/Address : 3626 North Hall Street (Two Oak Lawn), Suite 610, Dallas, TX 75219 USA.

Read the rest here:
Global Epigenetics Instrument Market 2022 Covid 19 Impact on Top countries data |Illumina, Thermo Fisher, Diagenode The Greater Binghamton Business...

DUBLIN--(BUSINESS WIRE)--The "Biomarkers Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global biomarkers market is expected to grow at a CAGR of 11.44%.

In-depth Analysis and Data-driven Insights on the Vendor Landscape, Competitive Analysis, and Critical Market Strategies are Included in this Global Biomarkers Market Report.

Biomarkers are increasingly useful tools to predict prognosis and response to therapy in cancer patients. Furthermore, it allows to improve understanding of mechanisms of action and resistance to treatment.

GLOBAL BIOMARKERS MARKET SEGMENTATION

Oncology dominated the indication segment because biomarkers are being largely used for cancer research and diagnostics due to its high prevalence worldwide. Biomarkers in the field of oncology has revolutionized the diagnostics and treatment pathways.

Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies is expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost

Diagnostic biomarker dominated the type of segment as diagnostic biomarker studies have entered a new era where it holds promise for early diagnosis and effective treatment of many diseases.

GEOGRAPHICAL ANALYSIS

North America dominated the geography because biomarkers have been in use highly for diagnostic purposes, drug discovery & development, and precision medicine. The increase in R&D expenditures and fundings for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors in all the regions.

APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance the biomarker-based testing and increasing demand for biomarkers in drug development and personalized medicine are one of the primary factors in the region.

KEY HIGHLIGHTS

Increased Adoption of Biomarkers in Personalized Medicine is driving the global biomarkers market growth. As many healthcare settings have gained interest in personalized/precision medicine, many vendors have increased the studies focusing on identifying biomarkers to provide healthcare system solutions to them.

Increasing focus on digital biomarkers will also drive the global Currently, several digital biomarkers are being tested for feasibility and reliability in Parkinson's and Alzheimer's disease and clinical outcome assessments.

Increasing discovery of epigenetic biomarkers for oncology is also driving the biomarker technologies market. There are more emerging companies increasing their research & development focus on discovering more epigenetics to diagnose various types of cancers.

Technological Advancements in Biomarker Discovery are also positively impacting the biomarkers diagnostics industry. For instance, a recent development in portable biosensors allows rapid, accurate, and on-site detection of biomarkers, which helps prevent disease spread by controlling sources.

VENDOR ANALYSIS

Multiple companies partnering and investing in biomarkers research and development will help the companies to innovate new drugs and reduce the economic burden.

Key Vendors

Other Prominent Vendors

Key Topics Covered:

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage

4.1 Market Definition

4.1.1 Inclusions

4.1.2 Exclusions

4.1.3 Market Estimation Caveats

4.2 Base Year

4.3 Scope of the Study

4.4 Market Segments

4.4.1 Market Segmentation by Indication

4.4.2 Market Segmentation by Application

4.4.3 Market Segmentation by Type

4.4.5 Market Segmentation by Geography

5 Report Assumptions & Caveats

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 Market at a Glance

7 Introduction

7.1 Overview

8 Market Opportunities & Trends

8.1 Increased Adoption of Biomarkers in Personalized Medicine

8.2 Increasing Focus on Digital Biomarkers

8.3 Increased Discovery of Epigenetic Biomarkers in Oncology

9 Market Growth Enablers

9.1 Increase in the Number of Pipeline Biomarkers

9.2 Rising Adoption of Biomarkers in Disease Diagnostics

9.3 Technological Advancements in Biomarker Discovery

10 Market Restraints

10.1 High Cost and Time-Consuming Development

10.2 High Number of False Discoveries

10.3 Strict Regulations and Ethics for Biomarker Validation & Qualification

11 Market Landscape

11.1 Market Overview

11.2 Market Size & Forecast

11.2.1 Insights by Indication

11.2.2 Insights by Application

11.2.3 Insights by Type

11.2.4 Insights by Geography

11.3 Five Forces Analysis

12 Indication

12.1 Market Snapshot & Growth Engine

12.2 Market Overview

12.3 Oncology

12.4 Cardiology

12.5 Neurology

12.6 Immunology

12.7 Others

13 Application

13.1 Market Snapshot & Growth Engine

13.2 Market Overview

13.3 Diagnostics

13.4 Drug Discovery & Development

13.5 Personalized Medicine

13.6 Others

14 Type

14.1 Market Snapshot & Growth Engine

14.2 Market Overview

14.3 Diagnostic Biomarkers

14.4 Monitoring Biomarkers

14.5 Prognostic Biomarkers

14.6 Predictive Biomarkers

14.7 Susceptibility Biomarkers

14.8 Other Biomarkers

15 Geography

15.1 Market Snapshot & Growth Engine

15.2 Geographic Overview

For more information about this report visit https://www.researchandmarkets.com/r/u2gu42

More:
Global Biomarkers Market Outlook & Forecast 2022-2027: Increase In Number of Pipeline Biomarkers & Rising Adoption of Biomarkers In Disease...

Part II of the Out of Despair series

EDITOR'S NOTE: The video above contains graphic images that may not be suitable for all audiences. Viewer discretion is advised.

By Betty Halliburton

The tragic murder of George Floyd two years ago, as the COVID-19 pandemic was accelerating, brought renewed focus to racial and health inequities in the U.S.

Northeast Ohio scholars and researchers say, however, that part of the reason it is such a difficult problem to address is that the historic racial wounds remain buried but not resolved.

We haven't addressed the trauma post-George Floyd nor have most of us addressed it from 400 years, said Angela Neal-Barnett, psychological sciences professor at Kent State University.

According to the National Institute of Mental Health, trauma is an experience that is emotionally painful, distressful and shocking. It is also rarely discussed in African American communities.

When you think about slavery, trauma, being separated from families, and what the ancestors of African Americans survived, their experience was something that got translated all the way down 400 generations, said Dr. Seema Patel, staff physician at Cleveland Clinics Center for Functional Medicine.

Trauma just went from one generation to the next generation, Dr. Patel said.

We look at the Holocaust victims and that has been well studied. We have not looked at African Americans who are descendants of slaves and the trauma that comes from that, she said.

Intergenerational trauma has been passed down from slavery

People captured in Africa were enslaved and packed tightly on top of each other into ships for the trip to the Americas, said Donna M. Whyte, Black Studies professor at Cleveland State University.

What I always think about is just the sway of the ship on the ocean and people lying down and their bodies chaffed, or even having to eat, having to eliminate all of this in the same space, Whyte said. So, it's understandable how so many people had diseases. They became ill, many died, and they also resisted.

1619 marked the arrival of the first recorded Africans in English North America after the long journey across the ocean called the Middle Passage.

I would be surprised if not every single person who endured [enslavement] had post-traumatic stress disorder (PTSD) as a result, said Monica Williams, a sought-after expert on racial trauma.

Williams who is a clinical psychologist, researcher and author from the University of Ottawa noted that racism is long, wide and deep.

It started from the very beginning when Black people were enslaved. To rationalize, enslaving another human being, this system was invented whereby there's white people and then everybody else who has less value, Williams said.

Many African Americans are dealing with transgenerational trauma, also known as intergenerational trauma. It can show up biologically, socially, mentally, and emotionally, experts said.

And it was never discussed. And it was never talked about. It just went from one generation to the next, she said.

We have looked at everything from reconstruction to Jim Crow to civil rights, and in that fight, in that struggle becomes stress and trauma, Akron Universitys Neal-Barnett said.

High rates of disease are connected to trauma and racism

Racism actually contributes to a lot of the healthcare disparities that we see in the area of medicine known as epigenetics, said Dr. Charles Modlin, a urologist and the medical director of inclusion, diversity and equity at MetroHealth.

Our bodies can be altered in terms of how our bodies interpret or express our genes, which can lead to higher rates of a lot of the diseases, Dr. Modlin said. And we see higher rates of obesity, diabetes, and high blood pressure.

In addition to physical ailments, Black people are also experiencing mental health issues related to racism and stress, said Neal-Barnett.

Our inability to address that trauma affects our mental health, which affects our physical health, she said.

The more racism you experience, the worse, your mental health, the worse, your physical health, and for many reasons. Dr. Williams said.

Both Williams and Neal-Barnett agree that more people of color should be trained and sent into the communities to bring more awareness about trauma and other mental health issues in places like barbershops, beauty salons and churches.

The healing begins when we talk about our trauma and realize that if it happened to you, it probably happened to someone in your family, your mother, your great grandmother and getting the help necessary is also vitally important, Neal-Barnett said.

This story is part of Connecting the Dots between Race and Health, a project of Ideastream Public Media funded by The Dr. Donald J. Goodman and Ruth Weber Goodman Philanthropic Fund of The Cleveland Foundation.

Originally posted here:
Many African Americans face unresolved trauma of racism and enslavement; It's affecting their health - ideastream

CALGARY, Alberta, May 10, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (Zenith or the Company) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical trial combining ZEN-3694 + Pfizer Inc.s Talzenna (talazoparib). The trial will continue to evaluate the efficacy and safety of this combination in patients with locally advanced or metastatic germline wild type BRCA1/2 TNBC. This Phase 2b trial is an extension of the recently completed Phase 1b/2 trial which met its primary efficacy endpoint of clinical benefit rate comprised of objective responses plus stable disease and which showed that the combination regimen was well tolerated. The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease.

The data from the Phase 1b/2 trial has shown that the ZEN-3694 plus talazoparib combination regimen induced durable responses in tumors of TNBC patients which do not harbor mutations in BRCA1/2," said Dr. Mark Robson, a principal investigator and medical oncologist at The Memorial Sloan Kettering Cancer Center. These clinical results confirm the rationale and data from pre-clinical experiments which have shown that BET inhibition can sensitize wild type BRCA1/2 TNBC tumors to PARP inhibition. This interesting data warrants the continued clinical evaluation of this combination.

In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.

Single agent PARPi are approved for gBRCAm HER2-negative locally advanced or metastatic breast cancer, as both PARP inhibition and non-functioning DNA repair proteins BRCA1/2 are required to block DNA repair and kill tumor cells (synthetic lethality). Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.

We are very pleased to advance our TNBC program to Phase 2b and closer to possible registration, said Donald J. McCaffery, President and CEO of Zenith. There is a significant unmet need in this aggressive cancer with few non cytotoxic therapy options available for the patient.

The data from the completed Phase 1b/2 part of the clinical trial will be presented in an oral poster discussion section at the annual ASCO conference in Chicago, Illinois on Monday, June 6, 2022. The abstract for this presentation will be released by ASCO on May 26, 2022, at 5:00 PM EDT on ASCO.org/Abstracts.

Abstract Number:1023

Abstract Title:A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.

Session Type/Title:Poster Discussion Session/Breast CancerMetastatic

Session Date and Time:Monday, June 6, 2022, 11:30 AM-1:00 PM; 8:00 AM-11:00 AM CDT

About Zenith and ZEN-3694

Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for various oncologic indications, specifically:

About Triple Negative Breast Cancer (TNBC)

TNBC is an aggressive form of breast cancer with low survival rates. TNBC accounts for about 10-15%of all breast cancers and it differs from other types of invasive breast cancer in that it tends to grow and spread faster, has fewer treatment options, and tends to have a worse prognosis. The termtriple-negative breast cancerrefers to the fact that the cancer cells have only low or no amount of the receptors ER, PR, and HER2. Approximately 75,000 women in the US, Japan and the major EU countries are diagnosed with TNBC each year.

For further information, please contact:

Investor Relations & Communications

Zenith EpigeneticsPhone: 587-390-7865Email: info@zenithepigenetics.comWebsite:www.zenithepigenetics.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the Companys development activities involving ZEN-3694 in combination with Pfizers PARP inhibitor Talzenna, and other targeted agents used in precision oncology, as well as other planned PARPi based combination therapy clinical trials in other tumor types. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our most recent MD&A which are incorporated herein by reference and are available through SEDAR at http://www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. Zenith disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise

See the original post:
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial - BioSpace

Watching Fear and Loathing in Las Vegas(now streaming on Peacock) with its frenetic pace, bizarre performances, and twisted cinematography is a visual experience akin to falling into a drug binge, and thats by design. The movie is constructed to give the feeling of living inside the minds of its two protagonists as they consume every illicit substance known to humanity, while supposedly on a work trip in Las Vegas. The result is an anxiety-laden two hours capturing a glimpse inside the mind of author Hunter S. Thompson.

While the movie has a certain amount of humor at the expense of its characters, driven mostly by the bombastic performances of Johnny Depp and Benicio del Toro, real-world substance dependence offers little to laugh about.

Long-term exposure to substances like alcohol, especially during adolescence not to mention the hard stuff found in the fictional Thompsons drug stash causes epigenetic changes to a persons brain chemistry which leads to dependence and anxiety disorders. According to a new study, gene editing by way of a modified version of CRISPR Cas9, might be able to reverse those changes in the brain.

Subhas Pandey from the Center for Alcohol Research in Epigenetics at the University of Illinois was the senior author of the study, now published in the journal Science Advances, which sought to reverse the negative effects of alcohol dependence in the brains of rats and, hopefully someday, in humans.

Adolescent binge drinking is a major public health concern, and it produces long lasting impacts on brain chemistry. So, its really important to catch the disease early and cure it before someone predisposes to substance abuse disorder, anxiety, and depression, Pandey told SYFY WIRE.

The research targeted the enhancer region of the activity-regulated cytoskeleton-associated protein, ARC for short, which is suppressed when individuals are exposed to chronic alcohol use in adolescence. According to Pandey, ARC is important for making connections between neurons so they can communicate with one another, and plays an important role in synaptic plasticity, learning, and memory. When its suppressed, alcohol consumption and anxiety behaviors increase.

Researchers used a modified version of CRISPER Cas9, known as dCAS9, which causes a functional change in a target gene without clipping it out. In this case, that meant researchers were able to increase ARC expression to undo the epigenetic damage caused by alcohol exposure.

In tests, rats were given alcohol between the 27th and 41st days of life, the equivalent of ages 10 to 18 in humans, which led to anxiety and increased alcohol consumption when the rats grew to adulthood. Then, they injected dCas9 into the amygdala to increase ARC expression. The process takes two weeks to go into full effect, but the results were impressive. Symptoms of anxiety as well as alcohol consumption decreased. The evidence suggests the relationship between gene expression and alcoholism or anxiety also holds for adults without early exposure to alcohol.

In a previous study, we found that chronic alcohol exposure in adulthood also leads to a reduction in the expression of this gene and causes anxiety-like behavior. In adult control animals, who are normal, if we do gene editing to suppress the expression of the ARC gene, they become anxious and start drinking more. So, it looks like this phenomenon is also important in adults, Pandey said.

Understanding the genetic and epigenetic drivers of anxiety and alcohol disorders, as well as gene editing strategies to address them, could lead researchers to novel therapies.

There are drugs which can manipulate this gene, but they may also affect several places in the brain, so we might get side effects because other genes are affected. Targeted manipulation of the gene, I personally feel, is the future of the medicine, Pandey said.

Hunter S. Thompson somehow straddled the line between brilliance and complete collapse, at least for a while. He was one of a kind, its unlikely there will ever be another like him. Especially now that gene editing can flip the off switch on our inner demons.

Go here to see the original:
Gene edited rats cured of anxiety and alcoholism | SYFY WIRE - Syfy

NEW YORK, NY Set before the 2016 presidential elections,Dreams on Fire, a groundbreaking play by Professor Jan Balakian and directed by Nora Armani, explores college students, mental health and the transmission of trauma in history across generations via the Armenian Genocide.

The play traces back the causes of Aram Sarkissians anxiety and mental health issues to intergenerational trauma through epigenetics. While the subject is dark, the characters are full of life and humor. The story takes place in Fort Lee, NJ and in retrospect prophetically refers to the four years of disastrous leadership that await the US. Arams grandmother Hripsime recounts the experiences of her own mother, surviving the Genocide as a young woman, and how she ends up in the US.

The riveting tale links the past to the present and explains mental health today as it is traced back to past trauma, even if such trauma has not touched the victim directly. Never before has there been a play that explores college students, mental health and the Armenian Genocide within the context of the 2016 election.

The cast of the Zoom reading includes Constance Cooper,Sam Arthur,Emma Giorgio andDalita Getzoyan. Donna Heffernan is assistant director. The reading, which is open to the public, will take place onWednesday, April 27, at 5:00 PM EDT presented as part of the Kean University Research Day activities. A Q&A session with Balakian, faculty members and attendees will follow the reading. FREE and open to the public.

The Armenian Genocide perpetrated by Ottoman Turkey on the Armenians is a fact widely substantiated by historians, archivists and eyewitnesses whose accounts have been recorded and preserved. And yet, the countries who have officially recognized it are few, mainly to appease Turkey.

US presidents, under pressure from Turkey, have played word gymnastics calling the events by several different names, shying away from its correct name of Genocide. President Joe Biden acknowledged the Armenian Genocide in 2021, and this year, on the 107th anniversary of the commemoration, confirmed that the events that started on April 24, 1915 and lasted until 1923, were in fact Genocide, causing the death of over 1.5 million Armenians and wiping out an entire population from its ancestral lands.

Guest contributions to the Armenian Weekly are informative articles or press releases written and submitted by members of the community.

Read the original here:
Dreams on Fire sheds light on epigenetics, collective trauma of genocide traveling through generations - Armenian Weekly

NEW ULM May is Mental Health Awareness Month, and this year the need for mental health education and services has never been higher.

Mental Health Month started in 1949 to increase awareness of the importance of mental health and wellness in Americans lives and to celebrate recovery from mental illness.

After more than two years of societal disruption from the COVID-19 pandemic, this year several Brown County organizations are working to promote the month.

Mental Health Awareness month is represented by a green ribbon. Throughout the month green ribbons will be displayed at the Community Service Building, 1117 Center St. and Brown County drop-in Center, 1113 Center St.

From 9 a.m. to 2:30 p.m. Tuesday, May 3, The Heart of New Ulm Brown County Mental Health and Wellbeing Action Team, in collaboration with the Families First Collaborative of Brown County, will be offering a presentation called Understanding NEAR Science: Building Self-Healing Communities.

The presentation covers the basics of NEAR science which stands for neurobiology, epigenetics, Adverse Childhood Experience (ACE) and resilience a study of the relationship between health risks and behaviors to exposure to adverse childhood experiences. People who experienced abuse, neglect or household dysfunction as a child were more likely to have increased risks of chronic health conditions and death, as well as increased participation in risky behaviors.

Additional research has shown experiences like racism, neighborhood safety, community violence, bullying, and living in foster care can increase the likelihood of increased health risks.

Over the last few decades, research has expanded on what can be done to prevent adverse childhood experiences and how people can move past their experiences to live healthy and safe lives.

The building self-healing communities presentation is intended to start an ongoing communitywide conversation between professionals, law enforcement, parents, faith leaders, educators and neighbors about how to change the narrative of the future of communities.

The Understanding NEAR Science: Building Self-Healing Communities presentation is free and open to the public; however, space is limited, and registration is required. For information and to register, visit https://tinyurl.com/NEARscience.

Similar presentation have been held in Brown County before, but due to the COVID pandemic few public health presentation were possible. The pandemic also created a need for greater need for mental health services as many were impacted by the health crisis.

The Brown County Local Advisory Committee will be hosting a Mental Health Walk Tuesday, May 17, Harman Park in New Ulm. The walk is open to everyone wishing to show support for mental health in the community. Registration for the walk is at 12:30 p.m. at Harman Park. There will be two routes to accommodate differing physical capabilities. The walk will be followed by professional speakers sharing their knowledge and experience regarding mental health recovery.

The local advisory committee is made of members of the public, professionals and providers with an interest in mental health and support in the county. The goal of the committee is to have a conversation about mental health, advocacy, combatting stigma and creating a supportive community for those struggling with their mental health.

Today's breaking news and more in your inbox

Read more:
NEAR science: good for what ails stressed communities - NUjournal

SIRIUS MANAGEMENT CONSULTING

The global biomarkers market was valued at $45 billion in 2021 and is expected to reach $86 billion by 2027.

Chicago, April 27, 2022 (GLOBE NEWSWIRE) -- According to the latest research report by Arizton, the biomarkers market will grow at a CAGR of over 11% during 2022-2027. Digital biomarkers have become an exciting new tool for advancing precision medicine and supporting clinical trials. They are collected using digital devices that are portable, wearable, implantable, or digestible. Digital biomarkers can be objective, quantifiable, physiological, and behavioral measures. Digital biomarkers have majorly impacted the neurology field. In neurology, several digital biomarkers are being tested for feasibility and reliability in Parkinsons and Alzheimer's disease and clinical outcome assessments.

With the emergence of innovative technologies, the identification and validation of a biomarker are becoming key elements of personalized medicine. For example, in cancer, personalized medicine uses specific biomarker information that has been measured from a persons tumor to help plan treatment regimes, monitor a treatments response, or aid in determining a prognosis.

BIOMARKERS MARKET REPORT SCOPE

REPORT ATTRIBUTE

DETAILS

MARKET SIZE (2027)

$86 Billion

CAGR (2022-2027)

Over 11%

BASE YEAR

2021

FORECAST YEAR

2022-2027

LARGEST MARKET

North America

FASTEST MARKET

Europe

MARKET SEGMENTATION

Indication, Application, Type, and Geography

REGION

North America, Europe, APAC, Latin America, and Middle East & Africa

COUNTRIES COVERED

US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, Argentina, Turkey, South Africa, and Saudi Arabia

KEY VENDORS

Abbott, bioMrieux, Biohit Oyj, Centogene, Creative Diagnostics, F. Hoffmann-La Roche, Fujirebio, GE Healthcare, TAmiRNA

Click Here to Download the Free Sample Report

The biomarker approach in developing personalized medicine helps in clinical decisions, personalized therapies, and improved research and development (R&D) models. Developing and providing access to novel personalized medicine products and services are only part of what is needed to achieve better human health by tailoring treatment based on the presence or absence of specific biomarkers.

Story continues

Increased Discovery of Epigenetic Biomarkers in Oncology

Epigenetics, genomic, and epigenomic technologies have opened new and promising landscapes for healthcare professionals, enabling them to diagnose and monitor diseases more precisely, effectively, and rapidly. It is obvious that epigenetics is revolutionizing the potential of biomedicine and clinical diagnostics, therefore, contributing to the future development of precision medicine.

Key Offerings:

Market Size & Forecast by Volume | 20212028

Market Dynamics Leading trends, growth drivers, restraints, and investment opportunities

Market Segmentation A detailed analysis by indication, application, type, and geography

Competitive Landscape 9 key vendors and 22 other vendors

To know more! https://www.arizton.com/market-reports/biomarkers-market

Key Insights

Biomarkers in the field of oncology have revolutionized diagnostics and treatment pathways. Oncology indications constitute of largest share because biomarkers are being largely used for cancer research and diagnostics due to their high prevalence worldwide.

Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies are expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost

North America is the largest market for biomarkers. The increase in R&D expenditures and funding for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors.

APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance biomarker-based testing and increasing demand for biomarkers in drug development is driving the demand in APAC.

The COVID-19 pandemic had a negative impact on the market. Several biomarkers research activities got postponed as most of the research activities were focused on COVID-19 indications.

Market Segmentation

Indication

Oncology

Cardiology

Neurology

Immunology

Others

Application

Type

Diagnostic Biomarker

Monitoring Biomarker

Prognostic Biomarker

Predictive Biomarker

Susceptibility Biomarker

Other Biomarker

Region

North America

Europe

Germany

France

UK

Italy

Spain

APAC

Japan

China

India

South Korea

Australia

Latin America

Middle East & Africa

Turkey

South Africa

Saudi Arabia

Competition Overview

The biomarkers market is highly dynamic, with the presence of several global, regional, and local players engaged in biomarkers discovery and development in collaboration with several research organizations. The growth of the biomarkers market majorly depends on advancements in technology and investments in R&D to discover and develop more biomarkers. Global players are focusing on developing more biomarkers and expanding their product portfolio to remain competitive in the market. The key players are also engaged in strategic acquisitions as part of their inorganic growth strategy to remain competitive and grow in the market. Through mergers & acquisitions, major players continue to expand their market shares. Furthermore, they are also growing through partnerships and collaborations with several research organizations to develop biomarkers for new testing strategies.

Explore our healthcare lifesciences profile to know more about the industry.

Click Here to Download the Free Sample Report

Read some of the top-selling reports:

About Arizton:

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Click Here to Contact Us

Call: +1-312-235-2040+1 302 469 0707

See the rest here:
Digital biomarkers - An Emerging tool in precision Medicines. The Biomarkers Market to Reach $86 Billion by 2027 - Arizton - Yahoo Finance

Sprint Bioscience today announces that the NIMA program is focused on developing a precision medicine treatment that targets the protein Nicotinamide N-methyl transferase (NNMT). The program will be launched in connection with Sprint Bioscience participating in the pharmaceutical industry's largest annual partnering meeting, BIO International Convention, in San Diego, June 13-16, 2022.

The NNMT gene is overexpressed in multiple cancers and high levels of NNMT is linked to poor prognosis in several tumor types, including gastric cancer, ovarian cancer and glioblastoma. Glioblastoma, which is one of the most aggressive cancers, accounts for about 35 percent of all brain tumors and is thus one of the main challenges in today's cancer care. The median survival for patients with glioblastoma is approximately 1214 months. Gastric cancer is the fifth most common cancer globally and the median survival for metastatic gastric cancer is only 15-17 weeks. Consequently, there is a large remaining unmet medical need for improved treatment alternatives for these indications.We are very pleased with the progress of the NIMA program, which entails atruly promising opportunity to develop a novel cancer treatment alternative. Our fragment-based drug development platform has enabled us once more to rapidly develop highly potent inhibitors of a novel target. We are very much looking forward to introducing the NIMA program to potential partners", said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.About the NNMT protein and cancerThe NNMT protein is upregulated in several cancers and is involved in various important processes in the survival of cancer cells at the interface between epigenetics, tumor metabolism and immunosuppression.

Upregulation of NNMT has been shown to promote tumor growth through epigenetic reprogramming of both cancer cells and stromal cell types in the tumor. Elevated NNMT have also been shown to affect cell metabolism, such as levels of S-adenosylmethionine (SAM) and biosynthesis of NADH. The product produced by NNMT, 1-methylnicotinamide (1MNA), is excreted by tumor cells and inactivates the function of immune cells in the tumor.

Studies have also shown that the ability of CAR-T cells to eliminate tumor cells is affected by 1MNA, which opens up for treatments where NNMT inhibitors can be used in combination with various types of immunotherapies, including cell therapies such as CAR-T.

Read more from the original source:
Sprint Bioscience's NIMA program is focused on the target protein NNMT and will be launched at the BIO International convention - Marketscreener.com